Compare VIASP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Via Renewables Inc. 8.75% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock
Current Price
| Metric | VIASP | SCLXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 160 | 31 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | VIASP | SCLXW |
|---|---|---|
| Price | $25.58 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 4.0K |
| Earning Date | N/A | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | N/A | $0.18 |
| 52 Week High | N/A | $0.18 |
| Indicator | VIASP | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 42.90 |
| Support Level | $25.49 | $0.17 |
| Resistance Level | $25.58 | $0.21 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 100.00 | 47.62 |
Via Renewables Inc is an independent retail energy services company. It provides residential and commercial customers in competitive markets across the United States with an alternative choice for natural gas and electricity. Via Renewables offers its customers a variety of product and service choices, including stable and predictable energy costs and green product alternatives. Its segments are Retail Electricity and Retail Natural Gas. The key revenue is derived from the Retail Electricity segment in which the company purchases electricity supply through physical and financial transactions with market counterparties and ISOs and supplies electricity to residential and commercial consumers pursuant to fixed-price and variable-price contracts.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.